Progranulin is upregulated in many tumors, as compared to normal tissues, suggesting that progranulin can serve as a biomarker for several cancer types, including breast, prostate, ovarian, colon and bladder cancers, non-small cell lung carcinoma and brain tumors. This evidence concerns the gene GRN and cancer.